BASELINE PREDICTORS OF SURVIVAL AND SPLEEN RESPONSE IN RUXOLITINIB- TREATED MYELOFIBROSIS: DEVELOPMENT OF THE RUXOLITINIB-PROGNOSTIC SCORING SYSTEM IN A REAL-WORLD COHORT (SIE 2026) - Oct 6, 2026 - Abstract #DP203; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "RUX remains an effective standard of care for MF. In this context, the clinically-based tool R-PSS may help in identifying pts at high risk of treatment failure, allowing optimal patient selection for novel therapies and/or allo-H- SCT referral soon after RUX-start."
Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Fibrosis • Hematological Disorders • Immunology • Myelofibrosis
|
|
A. Laganà; E. Scalzulli; M. L. Bisegna; I. Carmosino; D. Kasmi; M. Gherardini; A. L. Faccini; C. Andriola; M. Martelli; M. Breccia
|